Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing & Reimbursement

Set Alert for Pricing & Reimbursement

From China With Discount? BeiGene Moves Towards First Global PD-1 Green Light

Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.

China ImmunoOncology

Outside Oncology: 6 Updates From Roche's Pharma Investor Day

Management updated investors on M&A strategy, US drug pricing reform and R&D investment.

Business Strategies Companies

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private. 

Pricing Debate M & A

Biogen Says Physician Debate About Aduhelm More ‘Pervasive’ Than Anticipated

CEO Michel Vounatsos and US president Alisha Alaimo outlined plans to overcome the Alzheimer’s drug’s launch challenges and hinted at lower sales expectations at a Morgan Stanley investor event.

Launches Reimbursement

Pharma On Its Back Foot As US Drug Price Reform Advances

Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.

Pricing Debate Politics

JW Therapeutics Wins China’s Second CAR-T Approval

The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.

China Approvals

All Systems Go For Novartis 'World-First' Leqvio Pact With England

A price has finally been agreed for Novartis's small interfering RNA therapy and over the next three years, NHS England now expects to treat about 300,000 patients at high risk of a second cardiovascular event with inclisiran.

Cardiovascular Market Access

Some Winners Emerge Despite China’s Reimbursement Price-Cutting Scheme

Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.

China Sales & Earnings

Stock Watch: The Biotech Departure Lane From Europe

It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.

Pricing Strategies Reimbursement

The Booming Business Of Drug Exclusions

The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.

Market Access Reimbursement

Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients

The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose. 

Clinical Trials Strategy

Ascendis Will Take On Daily Genotropin With Weekly Skytrofa

Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.

Approvals Pricing Strategies
See All
UsernamePublicRestriction

Register